"Since transforming the BPH market, Aquablation has as given a degree of confidence for the surgeon as well as for the patient," says Ravi Munver, MD.
In this video, Ravi Munver, MD, highlights the positive impact that Aquablation has had for both patients and urologists in the management of BPH. Munver is the vice chair of the department of urology at Hackensack University Medical Center (HUMC), as well as the director of minimally invasive and robotic urologic surgery, the chief of living donor kidney surgery, and the director of the minimally invasive robotic laparoscopic and reconstructive oncology fellowship program at HUMC in New Jersey.
The impact has been overwhelming positive responses from patients that have undergone the therapy. I have used many therapies over the course of the year, many transurethral therapies as well as robotic therapies for treatment of BPH. When I say robotic, I'm meaning robotic assisted surgery to perform a robotic simple prostatectomy for the very large prostates that may not have been as amenable to some of these minimally invasive transurethral therapies. What I've found, since transforming the BPH market, Aquablation has as given a degree of confidence for the surgeon as well as for the patient. The minimal [adverse] effects compared to some of the other resective therapies, such as laser therapies and transurethral resection, is definitely noticeable. Being able to treat large prostates in a very short amount of time is also a significant difference compared to the other therapies, and reproducibility. I think the learning curve with Aquablation is a very short, and because of that, this is a procedure that I believe will be standardizable across urologists of all different ages and all different skill sets.
This transcription has been edited for clarity.